Another look at Week to March 4 news

5 March 2016

By Barbara Obstoj-Cardwell. Editor

Denmark’s pharmaceutical industry is going head-to-head with its Swedish counterpart by arguing Denmark should be the new home of the European Medicines Agency (EMA) if Britain votes to leave the European Union in the June 23 referendum, according to a report by EurActive. The EMA, which approves medicines for all EU countries, has been based in London since its inception in 1995, but a “Brexit” could force it to relocate to a new city inside the bloc.

“We will put pressure on the government to do everything it can to attract the European agency to Denmark,” Ida Sofie Jensen, head of the Danish Association of the Pharmaceutical Industry, told the MedWatch trade publication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK